Esperion to Report Third Quarter 2024 Financial Results on November 7
24 October 2024 - 11:00PM
Esperion (NASDAQ: ESPR) today announced it will report third
quarter 2024 financial results before the market opens on Thursday,
November 7, 2024.
Following the release, management will host a webcast at 8:00
a.m. ET to discuss these financial results and provide business
updates. Please click here to pre-register to participate in the
conference call and obtain your dial in number and PIN.
A live audio webcast can be accessed on the investor and media
section of the Esperion website. Access to the webcast replay will
be available approximately two hours after completion of the call
and will be archived on the Company's website for approximately 90
days.
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information: Investors: Alina
Veneziainvestorrelations@esperion.com (734) 887-3903
Media: Tiffany Aldrich corporateteam@esperion.com (616)
443-8438
This press release was published by a CLEAR® Verified
individual.
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Dec 2023 to Dec 2024